Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled heparin for cystic fibrosis pulmonary symptoms
ACTRN12610000328077Phase 2Recruiting
- Sponsor
- Vectura
- Start
- Jan 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised trial of heparin in cystic fibrosis (CF), sponsored by Vectura. Primary endpoint: Safety and tolerability. Started Jan 2009; status: recruiting.
02
Drugs
heparin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12610000328077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000328077.